PHARMAKINETICS CITED FOR PROTOCOL VIOLATIONS IN BIO STUDIES
PHARMAKINETICS CITED FOR PROTOCOL VIOLATIONS IN BIO STUDIES in a Dec. 20 warning letter sent by FDA's Division of Scientific Investigations to the Baldmore contract clinical research firm. "Your firm has violated FDA regulations in failing to follow the protocol with respect to subject inclusion/exclusion criteria, failing to document the medical basis for the discretionary inclusion of subjects who did not meet the inclusion criteria and failing to inform the IRB [institutional review board] of protocol changes," the warning letter charges.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth